Skip To Main Content

Scientific congress posters and presentations 

Medically.gene.com
Genentech maintains a presence at in-person and virtual scientific congresses worldwide. Find our complete congress presentation library at Medically, and review our most recent ophthalmology presentations below.

Vabysmo (faricimab-svoa)

Ophthalmology product information

Product information

Use the links below to browse and download important healthcare provider resources for VABYSMO.

Prescribing information

Ophthalmology publications

Publications

Visit PubMed.gov to browse Genentech’s comprehensive library of VABYSMO scientific literature.
Phase III clinical trial publications appear below.*

TENAYA/LUCERNE

Heier JS, Khanani AM, Quezada Ruiz C, et al.  Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase-3, non-inferiority trials. Lancet 2022 Feb 19; 399 (10326): 729-740. https://doi.org/10.1016/S0140-6736(22)00010-1

YOSEMITE/RHINE

Wykoff CC, Abreu F, Adamis AP, et al.  Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 2022 Feb 19; 399 (10326): 741-755. https://doi.org/10.1016/S0140-6736(22)00018-6

Ophthalmology clinical trials

Clinical trials

Find information about active clinical research for VABYSMO at ClinicalTrials.gov.

Susvimo (ranibizumab injection)

Ophthalmology product information

Product information

Use the links below to browse and download important healthcare provider resources for SUSVIMO.

Prescribing information

Susvimo™ Initial Fill & Implant Instructions

Susvimo™ Implant Removal Instructions

Medication guide

Safety data sheets:

SUSVIMO 10MG/0.1ML VIAL

Ophthalmology publications

Publications

Visit PubMed.gov to browse Genentech’s comprehensive library of SUSVIMO scientific literature.
Phase III clinical trial publications appear below.*

ARCHWAY

Holekamp N, Campochiaro P, Chang M, et al. Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2021. Ophthalmology 2022 Mar; 129 (3): 295-307. https://www.ncbi.nlm.nih.gov/pubmed/34597713

Ophthalmology clinical trials

Clinical trials

Find information about active clinical research for SUSVIMO at ClinicalTrials.gov.

Lucentis® (ranibizumab)

Ophthalmology product information

Product information

Use the links below to browse and download important healthcare provider resources for LUCENTIS.

Prescribing information

Healthcare provider letters

Safety data sheets:

LUCENTIS® Prefilled Syringe (0.5 mg/0.05 ml)

LUCENTIS® Prefilled Syringe (0.3 mg/0.05 ml)

LUCENTIS® Vials (0.3 mg/0.05 ml)

LUCENTIS® Vials (0.5 mg/0.05 ml)

Ophthalmology publications

Publications

Visit PubMed.gov to browse Genentech’s comprehensive library of LUCENTIS scientific literature.
Phase III clinical trial publications appear below.*

RISE and RIDE

Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801. http://www.ncbi.nlm.nih.gov/pubmed/22330964

Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two Phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-2022. http://www.ncbi.nlm.nih.gov/pubmed/23706949

Protocol S

Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial [supplementary appendix appears online]. JAMA 2015;314:2137-2146. JAMA 2015 Nov 24; 314 (20): 2137-2146. https://pubmed.ncbi.nlm.nih.gov/26565927/

MARINA

Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. http://www.ncbi.nlm.nih.gov/pubmed/17021318.

ANCHOR

Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. http://www.ncbi.nlm.nih.gov/pubmed/17021319.  

Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65. http://www.ncbi.nlm.nih.gov/pubmed/19118696

PIER

Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239-248. http://www.ncbi.nlm.nih.gov/pubmed/18222192.

HARBOR

Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-1056. https://pubmed.ncbi.nlm.nih.gov/23352196/

Ho AC, Busbee BG, Regillo CD, et al.  Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014;121:2181-2192. https://pubmed.ncbi.nlm.nih.gov/25015215/.

RADIANCE

Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014;121:682-692.e2. https://www.ncbi.nlm.nih.gov/pubmed/24326106.

BRAVO

Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary endpoint results of a Phase III study. Ophthalmology 2010;117:1102-1112. http://www.ncbi.nlm.nih.gov/pubmed/20398941.

CRUISE

Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 2010;117:1124-1133.e1. http://www.ncbi.nlm.nih.gov/pubmed/20381871.

Ophthalmology clinical trials

Clinical trials

Find information about active clinical research for LUCENTIS at ClinicalTrials.gov.

Ophthalmology Resources

Ophthalmology at Genentech
Visit Genentech.com to learn more about advancements in ophthalmology research and treatment.

Ophthalmology at Roche
Visit Roche.com to learn more about advancements in ophthalmology research and treatment.

 

*Browse Phase III Genentech publications that have been published in peer-reviewed journals. Publications are limited to products approved for use in the US. The list of publications may contain information that falls outside of the approved US prescribing information.